Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2006	FY 2005	FY 2004
Period Ending	Jun '07 Jun 30, 2007	Dec '06 Dec 31, 2006	Dec '05 Dec 31, 2005	Dec '04 Dec 31, 2004
Revenue	0.07	0.42	0.05	0.04
Revenue Growth (YoY)	-80.90%	719.48%	42.90%	-
Cost of Revenue	0.2	0.14	0.03	0.01
Gross Profit	-0.13	0.28	0.03	0.02
Selling, General & Admin	0.54	0.83	0.31	0.58
Research & Development	0.01	0.02	-	-
Other Operating Expenses	-0	-0	0	0
Operating Expenses	0.55	0.85	0.34	0.58
Operating Income	-0.68	-0.57	-0.32	-0.56
Interest Expense	-0.01	-0.01	-0.01	-
Other Non Operating Income (Expenses)	-0.04	-0.04	-0.02	-0
EBT Excluding Unusual Items	-0.72	-0.61	-0.35	-0.56
Merger & Restructuring Charges	-0.12	-0.12	-	-
Pretax Income	-0.84	-0.73	-0.35	-0.56
Net Income	-0.84	-0.73	-0.35	-0.56
Net Income to Common	-0.84	-0.73	-0.35	-0.56
Shares Outstanding (Basic)	0	4	2	2
Shares Outstanding (Diluted)	0	4	2	2
Shares Change (YoY)	-93.58%	102.80%	-10.11%	-
EPS (Basic)	-3.75	-0.17	-0.16	-0.23
EPS (Diluted)	-3.75	-0.17	-0.16	-0.23
Free Cash Flow	-0.64	-0.89	-0.7	-0.78
Free Cash Flow Per Share	-2.82	-0.20	-0.32	-0.32
Gross Margin	-197.94%	65.66%	50.05%	62.82%
Operating Margin	-1007.26%	-136.09%	-623.17%	-1551.33%
Profit Margin	-1252.90%	-174.94%	-681.48%	-1565.03%
Free Cash Flow Margin	-942.64%	-211.95%	-1369.58%	-2166.11%
EBITDA	-	-	-0.29	-
D&A For EBITDA	-	-	0.03	-
EBIT	-0.68	-0.57	-0.32	-0.56
EBIT Margin	-	-136.09%	-	-
Revenue as Reported	0.43	0.43	-	-
Advertising Expenses	-	0.1	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.